For health care professionals in EUROPE except those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
A global evaluation of advanced dosimetry in transarterial radioembolisation of hepatocellular carcinoma with Yttrium-90: the TARGET study.
The TARGET study confirms TheraSphere treatment for HCC as safe and effective in select patient populations. Predictable clinical outcomes from this real-world study span a broad group across 8 countries.
Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0.
Establish the relationships between:
*TheraSphere not indicated for patients with PVT.
70.8% ORR*
for the target lesion (mRECIST)
61.7% OR**
for all lesions (mRECIST)
20.3 months
median overall survival
*95% CI 64.3, 76.6
**95% CI 55.0, 68.0
Responders had a
17% higher
mean tumour absorbed dose (225.5 Gy*) compared with non-responders (188.3 Gy**)
*95% CI 201.0 - 253.0 Gy
**95% CI 164.6 - 215.3 Gy; p = 0.046
Kaplan-Meier overall survival curves
Total perfused tumour absorbed dose by subgroups
>300 Gy - 36.7 months
(95% CI: 20.2 - 43.9 months)
>200 - <300 Gy - 25.1 months
(95% CI: 14.5 - 32.9 months)
<200 Gy - 16.1 months
(95% CI: 11.3 - 19.4 months)
Only 4.8% of patients (10/209) experienced ≥ Grade 3 hyperbilirubinemia in the absence of disease progression.
Regarding the low rate of event, no correlation could be established with the normal tissue absorbed dose (p=0.6 for NTAD).
Deliver the highest dose to the tumour that is safely possible to maximise patient response and improve survival
Predictable results across 8 countries using multi-compartmental dosimetry using Simplicit90Y personalised dosimetry software
Like the Legacy study and Dosisphere-01 trial results, the Target study reinforces the association between higher tumour absorbed dose and clinical outcomes
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
TheraSphere is a registered trademark of Theragenics Corporation, used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation. Simplicit90Y is a registered trademark of Boston Scientific Medical Device Limited. Simplict90Y is developed by Mirada Medical Ltd. and used under license by Boston Scientific Corporation, the sales agent for Simplicit90Y. All rights reserved.
